Co-Administration of Adjuvanted Recombinant <i>Ov</i>-103 and <i>Ov</i>-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine <i>Onchocerca ochengi</i> Infection Model of Human Onchocerciasis
Onchocerciasis (river blindness), caused by the filarial nematode <i>Onchocerca volvulus</i>, is a neglected tropical disease mainly of sub-Saharan Africa. Worldwide, an estimated 20.9 million individuals live with infection and a further 205 million are at risk of disease. Current contr...
Main Authors: | Lisa Luu, Germanus S. Bah, Ndode Herman Okah-Nnane, Catherine S. Hartley, Alexandra F. Glover, Tessa R. Walsh, Lu-Yun Lian, Bin Zhan, Maria Elena Bottazzi, David Abraham, Nikolai Petrovsky, Nicolas Bayang, Bernard Tangwa, Rene Billingwe Ayiseh, Glory Enjong Mbah, David D. Ekale, Vincent N. Tanya, Sara Lustigman, Benjamin L. Makepeace, John Graham-Brown |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/6/861 |
Similar Items
-
Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans.
by: Parakkal Jovvian George, et al.
Published: (2019-09-01) -
Development and validation of an Onchocerca ochengi adult male worm gerbil model for macrofilaricidal drug screening.
by: Fidelis Cho-Ngwa, et al.
Published: (2019-07-01) -
The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
by: Fidelis Cho-Ngwa, et al.
Published: (2010-08-01) -
Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis.
by: Germanus S Bah, et al.
Published: (2021-06-01) -
UMF-078: A modified flubendazole with potent macrofilaricidal activity against <it>Onchocerca ochengi </it>in African cattle
by: deC Bronsvoort Barend M, et al.
Published: (2008-06-01)